ABBV icon

AbbVie

224.13 USD
-9.29
3.98%
At close Updated Jan 8, 4:00 PM EST
Pre-market
After hours
225.00
+0.87
0.39%
1 day
-3.98%
5 days
-2.02%
1 month
0.45%
3 months
-3.07%
6 months
18.11%
Year to date
-2.26%
1 year
25.56%
5 years
108.94%
10 years
302.75%
 

About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

Employees: 55,000

0
Funds holding %
of 7,536 funds
0
Analysts bullish %
of 10 analysts
0
Positive news %
of 48 articles
Price charts implemented using Lightweight Charts™